Publications
361
Citations
33,263
Est. group size
~8
Recurring co-author estimate
Active years
36
Publishing since 1991
Matthew D. Ringel's research centers on thyroid cancer, spanning molecular mechanisms of tumor growth and treatment resistance (such as BRAF gene mutations and radioresistance), genetics of inherited thyroid cancer syndromes, and clinical management questions like the use of radioactive iodine, surgery, and active surveillance for differentiated thyroid cancer. The work combines laboratory studies of cancer cell biology with clinical guideline development and systematic reviews aimed at informing patient care.
Publication output has grown substantially over the past decade, rising from single digits in 2017-2018 to a peak of 49 in 2024, though with some year-to-year fluctuation.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Identification of Rare Noncoding Variants in Familial Nonmedullary Thyroid Carcinoma
Thyroid · 2026
- Counseling Female Thyroid Cancer Patients on Radioactive Iodine and Fertility
Thyroid · 2026
- The evolution and validation of thyroid cancer guidelines as evidence advances toward individualized therapy
The Journal of Clinical Endocrinology & Metabolism · 2026
- In memoriam: Charis Eng MD PhD (1962–2024)
Endocrine Related Cancer · 2024
- Supplementary Data from Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAF<sup>V600E</sup>-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair
2023
- Supplementary Data from Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAF<sup>V600E</sup>-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair
2023
- Data from Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAF<sup>V600E</sup>-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair
2023
- Data from Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAF<sup>V600E</sup>-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair
2023
- A tribute to Ernest L. Mazzaferri, MD and the lasting impact that he had on thyroid cancer care ten years after his death
Endocrine · 2023
- Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review
Thyroid · 2022
- American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
Head & Neck · 2022
- Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review
Thyroid · 2022
- Faculty Opinions recommendation of Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2022
- Neoplasms of the Thyroid
Holland‐Frei Cancer Medicine · 2022
- Radioiodine: 80 years and counting; the past, present, and future
Endocrine Related Cancer · 2021
- Nature Communications×24
- Thyroid×17
- Nature×12
- Nature Genetics×11
- The Journal of Clinical Endocrinology & Metabolism×9
- Irina Azaryan
Medicine · The Ohio State University
- Ernest L. Mazzaferri
Medicine · The Ohio State University
- Fadi Nabhan
Medicine · The Ohio State University
- Jennifer A. Sipos
Medicine · The Ohio State University
- Michael Morkos
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile